was read the article
array:24 [ "pii" => "S1807593222023250" "issn" => "18075932" "doi" => "10.1590/S1807-59322011001000006" "estado" => "S300" "fechaPublicacion" => "2011-10-01" "aid" => "2325" "copyright" => "CLINICS" "copyrightAnyo" => "2011" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by-nc/3.0/" "subdocumento" => "fla" "cita" => "Clinics. 2011;66:1699-705" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S1807593222023262" "issn" => "18075932" "doi" => "10.1590/S1807-59322011001000007" "estado" => "S300" "fechaPublicacion" => "2011-10-01" "aid" => "2326" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by-nc/3.0/" "subdocumento" => "fla" "cita" => "Clinics. 2011;66:1707-12" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>" "titulo" => "The Brazilian Football Association (CBF) model for epidemiological studies on professional soccer player injuries" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1707" "paginaFinal" => "1712" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Gustavo Gonçalves Arliani, Paulo Santoro Belangero, Jose Luiz Runco, Moisés Cohen" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Gustavo Gonçalves" "apellidos" => "Arliani" ] 1 => array:2 [ "nombre" => "Paulo Santoro" "apellidos" => "Belangero" ] 2 => array:2 [ "nombre" => "Jose Luiz" "apellidos" => "Runco" ] 3 => array:2 [ "nombre" => "Moisés" "apellidos" => "Cohen" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222023262?idApp=UINPBA00004N" "url" => "/18075932/0000006600000010/v1_202212011334/S1807593222023262/v1_202212011334/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1807593222023249" "issn" => "18075932" "doi" => "10.1590/S1807-59322011001000005" "estado" => "S300" "fechaPublicacion" => "2011-10-01" "aid" => "2324" "copyright" => "CLINICS" "documento" => "article" "crossmark" => 0 "licencia" => "https://creativecommons.org/licenses/by-nc/3.0/" "subdocumento" => "fla" "cita" => "Clinics. 2011;66:1691-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>" "titulo" => "Concomitant prescribing and dispensing errors at a Brazilian hospital: a descriptive study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1691" "paginaFinal" => "1697" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 654 "Ancho" => 480 "Tamanyo" => 23977 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">A description of the selection process for prescriptions with high-alert medications (HAM).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Maria das Dores Graciano Silva, Mário Borges Rosa, Bryony Dean Franklin, Adriano Max Moreira Reis, Lêni Márcia Anchieta, Joaquim Antônio César Mota" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Maria das Dores Graciano" "apellidos" => "Silva" ] 1 => array:2 [ "nombre" => "Mário Borges" "apellidos" => "Rosa" ] 2 => array:2 [ "nombre" => "Bryony Dean" "apellidos" => "Franklin" ] 3 => array:2 [ "nombre" => "Adriano Max Moreira" "apellidos" => "Reis" ] 4 => array:2 [ "nombre" => "Lêni Márcia" "apellidos" => "Anchieta" ] 5 => array:2 [ "nombre" => "Joaquim Antônio César" "apellidos" => "Mota" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222023249?idApp=UINPBA00004N" "url" => "/18075932/0000006600000010/v1_202212011334/S1807593222023249/v1_202212011334/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CLINICAL SCIENCE</span>" "titulo" => "Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1699" "paginaFinal" => "1705" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Letícia Carvalho Neuenschwander, Henrique Bittencourt, Ana Flávia Tibúrcio Ribeiro, Antônio Lúcio Teixeira, Mauro M. Teixeira, Jairo Cerqueira Teixeira, Vandack Nobre" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Letícia Carvalho" "apellidos" => "Neuenschwander" ] 1 => array:2 [ "nombre" => "Henrique" "apellidos" => "Bittencourt" ] 2 => array:2 [ "nombre" => "Ana Flávia" "apellidos" => "Tibúrcio Ribeiro" ] 3 => array:2 [ "nombre" => "Antônio Lúcio" "apellidos" => "Teixeira" ] 4 => array:2 [ "nombre" => "Mauro M." "apellidos" => "Teixeira" ] 5 => array:2 [ "nombre" => "Jairo Cerqueira" "apellidos" => "Teixeira" ] 6 => array:4 [ "nombre" => "Vandack" "apellidos" => "Nobre" "email" => array:1 [ 0 => "vandack@medicina.umg.br" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Postgraduate Course in Infectious Diseases and Tropical Medicine, Internal Medicine Department, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte/MG, Brazil" "identificador" => "aff1" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Tel.: 55 31 98310004" ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 434 "Ancho" => 442 "Tamanyo" => 21801 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">ROC curve showing the accuracy of the four inflammatory molecules significantly associated with a change in antibiotic therapy within the first 72 h of therapy. The corresponding AUC values were 0.683 (CI 95%: 0.477–0.899) for PCT, 0.758 (CI 95%: 0.572–0.944) for MCP-1, 0.683 (95% CI: 0.470–0.896) for IL-8, and 0.696 (95% CI: 469–922) for sTNF-R II; all data were collected at day 3 following inclusion.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="cesec10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle60">INTRODUCTION</span><p id="para10" class="elsevierStylePara elsevierViewall">Neutropenia, a common feature in onco-hematological patients undergoing chemotherapy, is one of the most important risk factors for bacterial and fungal infections.<a class="elsevierStyleCrossRef" href="#bib1">1</a> Due to the potential life-threatening severity of this condition, a low threshold of clinical suspicion and prompt antimicrobial therapy are essential to effectively manage infectious complications in neutropenic patients.<a class="elsevierStyleCrossRef" href="#bib2">2</a> However, identifying infections in this population can be challenging, and fever is occasionally the only clinical sign.<a class="elsevierStyleCrossRef" href="#bib3">3</a></p><p id="para20" class="elsevierStylePara elsevierViewall">Risk stratification is also of the utmost importance when dealing with febrile neutropenic patients, as they constitute a heterogeneous population with a variable risk for serious complications.<a class="elsevierStyleCrossRefs" href="#bib4">4–5</a> Stratification allows the clinician to identify a subgroup of patients who might be safely treated with oral antibiotics.<a class="elsevierStyleCrossRefs" href="#bib6">6–7</a> In 1988 and 1992, Talcott et al. proposed and validated, respectively, a risk model for classifying patients with febrile neutropenia according to disease burden (remission <span class="elsevierStyleItalic">vs.</span> activity), presence of comorbidities, and the source of fever (i.e., community-acquired fever or nosocomial fever).<a class="elsevierStyleCrossRefs" href="#bib8">8–9</a> More recently, in a multicenter observational study, the Multinational Association for Supportive Care in Cancer (MASCC) derived a model to identify low-risk neutropenic patients (those with MASCC score ≥21 points), with 71% sensitivity and a 91% positive predictive value.<a class="elsevierStyleCrossRef" href="#bib10">10</a> Although useful, the Talcott and MASCC models have several limitations, chiefly their use of subjective, institution-dependent variables and high misclassification rates.<a class="elsevierStyleCrossRef" href="#bib11">11</a> Biological markers have been proposed as an additional tool for risk assessment in patients with febrile neutropenia. The accuracy and predictive value of these markers have been tested for clinical and laboratory endpoints (e.g., bacteremia and mortality) in small, single-center studies, but these results have been contradictory.<a class="elsevierStyleCrossRefs" href="#bib12">12–15</a> In general, these markers are better suited for the identification of low-risk patients, as they have high negative predictive values for severe complications.<a class="elsevierStyleCrossRef" href="#bib16">16</a></p><p id="para30" class="elsevierStylePara elsevierViewall">In this pilot study, we aimed to evaluate the plasma levels of different biological markers in febrile neutropenic patients and assess the relationship between these markers and detrimental clinical events.</p></span><span id="cesec20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle70">MATERIAL AND METHODS</span><span id="cesec30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle80">Patients and settings</span><p id="para40" class="elsevierStylePara elsevierViewall">We conducted a prospective, single-center study of patients with febrile neutropenia admitted to the hematological ward of a tertiary general hospital in Belo Horizonte, Brazil. All adult patients (age ≥18 years) admitted to the University Hospital of the Universidade Federal de Minas Gerais (UH-UFMG) from September 2008 to March 2009 with an onco-hematological diagnosis and febrile neutropenia were evaluated for eligibility. The UH-UFMG is a 460-bed general hospital that is a regional reference center for the management of highly complex conditions, including onco-hematological diseases.</p><p id="para50" class="elsevierStylePara elsevierViewall">Patients with a neutrophil count less than 1,000/mm<span class="elsevierStyleSup">3</span> were evaluated by two dedicated investigators and invited to participate in the study if they met the following inclusion criteria: <span class="elsevierStyleItalic">(i)</span> a primary diagnosis of an onco-hematological disease; <span class="elsevierStyleItalic">(ii)</span> a neutrophil count less than 500 per mm<span class="elsevierStyleSup">3</span> or a neutrophil count less than 1,000 per mm<span class="elsevierStyleSup">3</span> that was expected to fall below 500 per mm<span class="elsevierStyleSup">3</span> within the next 48 h, with an anticipated duration of neutropenia of at least six days; <span class="elsevierStyleItalic">(iii)</span> fever, defined as an axillary temperature greater than 37.8°C in two consecutive readings at least one hour apart or a single reading greater than 38.3°C; and <span class="elsevierStyleItalic">(iv)</span> either scheduled antibiotic therapy or prior antibiotic therapy for less than one day. Patients were excluded from the study if they presented with a fever that was clearly regarded by the attending physician as being of a non-infectious origin and for which no antibiotic therapy was initiated. Finally, inclusion was considered for individual episodes of febrile neutropenia, and the same patient could be included more than once, provided the episodes of febrile neutropenia occurred during different hospitalization periods.</p><p id="para60" class="elsevierStylePara elsevierViewall">The exclusion criteria were as follows: <span class="elsevierStyleItalic">(i)</span> antibiotic therapy for more than 24 h at the time of inclusion or <span class="elsevierStyleItalic">(ii)</span> presentation with severe organ dysfunction (<span class="elsevierStyleItalic">e.g</span>., use of vasoactive amines or mechanical ventilation).</p><p id="para70" class="elsevierStylePara elsevierViewall">The variables recorded included age, gender, comorbidities, source of infection (when known), primary diagnosis and its state, current antibiotic therapy, and chemotherapeutic regimens. The presence of comorbidities was measured using the modified Charlson's score.<a class="elsevierStyleCrossRef" href="#bib17">17</a> We also determined each patient's MASCC risk index, a scoring system for identifying low-risk febrile neutropenic cancer patients<a class="elsevierStyleCrossRefs" href="#bib10">10,18</a> at baseline. Variables recorded daily during the follow-up included hemodynamic and respiratory parameters and any changes in antibiotic therapy. All-cause 28-day mortality and length of hospital stay were also recorded.</p><p id="para80" class="elsevierStylePara elsevierViewall">The Ethics Committee of the Universidade Federal de Minas Gerais approved this study, and all included patients provided written, informed consent. In conducting this study and writing this report, we adhered to the Standard for Reporting of Diagnostic Accuracy studies checklist and recommendations.<a class="elsevierStyleCrossRef" href="#bib19">19</a></p></span><span id="cesec40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle90">Endpoints</span><p id="para90" class="elsevierStylePara elsevierViewall">The evaluated endpoints were <span class="elsevierStyleItalic">(i)</span> any change in antibiotic regimen within the first 72 h of therapy, as determined by the attending physician; <span class="elsevierStyleItalic">(ii)</span> bacteremia; and <span class="elsevierStyleItalic">(iii)</span> all-cause 28-day mortality.</p><p id="para100" class="elsevierStylePara elsevierViewall">A change of antibiotic regimen was defined as one of the following two situations: <span class="elsevierStyleItalic">(i)</span> the addition of a new antimicrobial agent with a broader or different spectrum compared with the current treatment, or <span class="elsevierStyleItalic">(ii)</span> a complete change in the antimicrobial regimen for any reason other than adverse effects related to the previous agents.</p><p id="para110" class="elsevierStylePara elsevierViewall">Bacteremia was defined as the growth of any pathogenic microorganism in one or more blood samples or the growth of representative skin microorganisms (e.g., coagulase-negative staphylococci) in at least two blood samples obtained from different sites.</p></span><span id="cesec50" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle100">Procedures</span><p id="para120" class="elsevierStylePara elsevierViewall">All the included patients underwent a clinical evaluation at baseline, including clinical anamnesis and a physical examination. Peripheral blood samples were collected using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, São Paulo, Brazil) in the morning on the initial day of fever (inclusion or day 0) and subsequently on days 1, 3, and 7. Approximately 2–3 ml of plasma was obtained from each blood sample and stored at -80°C.</p><p id="para130" class="elsevierStylePara elsevierViewall">The management of patients with febrile neutropenia followed the recommendations proposed by the Infectious Diseases Society of America.<a class="elsevierStyleCrossRef" href="#bib3">3</a> Briefly, two blood culture samples were obtained for all neutropenic (see the above inclusion criteria) patients with fever or unexplained clinical deterioration. Urine cultures and imaging were performed as clinically indicated. The empirical antibiotic regimen used for the first episode of febrile neutropenia was monotherapy with cefepime or a combination of ceftazidime and an aminoglycoside. If risk factors for staphylococcal infection were observed (<span class="elsevierStyleItalic">e.g</span>., catheter-related infection, shock, or mucositis), vancomycin was added to the antimicrobial regimen.</p><p id="para140" class="elsevierStylePara elsevierViewall">The included patients were followed for 28 days or until death or transfer/discharge from the hospital, whichever occurred first.</p></span><span id="cesec60" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle110">Laboratory exams</span><p id="para150" class="elsevierStylePara elsevierViewall">Plasma levels of nine inflammatory molecules were evaluated in this study: procalcitonin (PCT), induced protein-10 (IP-10), tumor necrosis factor alpha (TNF-α), soluble TNF-α receptors type I and type II (sTNF-R I and sTNF-R II), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1-alpha (MIP-1α), and eotaxin. All assays were performed at the end of the inclusion period; thus, there was no interference in the management of the studied patients. Plasma levels of TNF-α, sTNF-R I, sTNF-R II, MIP-1α, IL-8, eotaxin, IP-10, and MCP-1 were measured using a sandwich enzyme-linked immunoassay (ELISA) (Duoset R & D Systems, Minneapolis, MN, USA). The PCT level was measured using an enzyme-linked fluorescent immunoassay (PCT Vidas Brahms, bioMérieux, France), with an assay sensitivity of 0.05 μg/L, which is approximately four times greater than the mean normal level.</p></span><span id="cesec70" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle120">Statistical analysis</span><p id="para160" class="elsevierStylePara elsevierViewall">Discrete variables are expressed as percentages, and continuous variables are presented as the mean ± SD for normally distributed variables or as the median and range for non-normally distributed variables. The data were analyzed using a χ<span class="elsevierStyleSup">2</span> test (Yates' test or Fisher's exact test), a two-sample <span class="elsevierStyleItalic">t</span>-test, or a Mann-Whitney <span class="elsevierStyleItalic">U</span> test, as appropriate. Age, gender, main hematological diagnosis and all-cause 28-day mortality were analyzed for the total number of patients included in the study. All other analyses were performed taking into account the total number of episodes of febrile neutropenia included in the study. ROC curves were constructed to establish the accuracy of each studied marker in predicting the proposed endpoints. Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were calculated once the best cut-off levels of these molecules were defined. The collected data were entered into a relational database (Excel 2000; Microsoft, Redmond, WA) and then converted into SPSS files (SPSS 15.0; SPSS, Chicago, United States) for the analyses. A <span class="elsevierStyleItalic">p-</span>value less than 0.05 was considered significant.</p></span></span><span id="cesec80" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle130">RESULTS</span><span id="cesec90" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle140">Characteristics of the patients</span><p id="para170" class="elsevierStylePara elsevierViewall">Overall, 222 episodes of neutropenia were assessed for eligibility. From these, 37 episodes of febrile neutropenia observed in 31 patients met the enrollment criteria and were included in the final analysis. The main characteristics of the included episodes are shown in <a class="elsevierStyleCrossRef" href="#tbl1">Table I</a>. Of the 31 included patients, 23 (74.2%) were male, and the mean (±SD) age of the cohort was 38.5 (±12.3) years. The main hematological diagnoses were acute myeloid leukemia (10 episodes; 32.3%), non-Hodgkin's lymphoma (7 episodes; 22.5%), or multiple myeloma (5 episodes; 16.1%) (<a class="elsevierStyleCrossRef" href="#tbl1">Table I</a>).</p><elsevierMultimedia ident="tbl1"></elsevierMultimedia><p id="para180" class="elsevierStylePara elsevierViewall">Of the 37 included episodes of febrile neutropenia, 22 (59%) were secondary to chemotherapy for the hematological disease, and 15 (41%) episodes occurred after bone marrow transplantation (9 allogeneic and 6 autologous). Other than fever, most cases did not present signs or symptoms suggestive of infection. Mucositis was observed in eight (21%) episodes. Two patients (2%) presented with smooth-tissue abscesses.</p><p id="para190" class="elsevierStylePara elsevierViewall">Based on the MASCC model, 75% of the episodes were classified as low risk (score ≥21 points). Furthermore, 21 (59%) episodes had an ECOG of 0 or 1; that is, the patients were fully active or only physically strenuous activity was restricted. Finally, as measured using the modified Charlson's score, most patients did not present with any comorbidities (<a class="elsevierStyleCrossRef" href="#tbl1">Table I</a>).</p></span><span id="cesec100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle150">Inflammatory molecules and antibiotic regimen change</span><p id="para200" class="elsevierStylePara elsevierViewall">In 12 (32%) episodes of febrile neutropenia, a change in antimicrobial regimen was necessary during the first 72 h of treatment. The circulating levels of sTNF-R II (<span class="elsevierStyleItalic">p</span> = 0.036), IL-8 (<span class="elsevierStyleItalic">p</span> = 0.047), MCP-1 (<span class="elsevierStyleItalic">p</span> = 0.008), and PCT (<span class="elsevierStyleItalic">p</span> = 0.038), measured at day 3, were significantly higher in patients requiring a change in antibiotic regimen compared with those not requiring a change. <a class="elsevierStyleCrossRef" href="#tbl2">Table II</a> depicts the best cut-off levels for these markers, as defined by the receiver operating ROC curve (<a class="elsevierStyleCrossRef" href="#fig1">Figure 1</a>), as well as the corresponding accuracy. Based on these data, the PCT level had the highest positive predictive value for identifying patients requiring an adjustment in antimicrobial therapy (83%).</p><elsevierMultimedia ident="tbl2"></elsevierMultimedia><elsevierMultimedia ident="fig1"></elsevierMultimedia></span><span id="cesec110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle160">Inflammatory molecules and bacteremia</span><p id="para210" class="elsevierStylePara elsevierViewall">Of the 37 episodes of febrile neutropenia, 13 (35%) presented with a positive blood culture during hospitalization. Overall, 15 species were isolated, with two patients presenting with mixed sepsis. Gram-positive (eight cases) and Gram-negative (seven cases) bacteria were similarly represented, with coagulase-negative staphylococci, <span class="elsevierStyleItalic">S. aureus</span>, <span class="elsevierStyleItalic">Escherichia coli</span> and <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> being the most frequently isolated species. None of the markers examined showed an association with bacteremia.</p></span><span id="cesec120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle170">Inflammatory molecules and all-cause 28-day mortality</span><p id="para220" class="elsevierStylePara elsevierViewall">Nine (29%) of the thirty-one patients died during the follow-up period. The circulating levels of sTNF-R II measured at day 1 (<span class="elsevierStyleItalic">p</span> = 0.034) and the PCT level measured on the day of fever presentation (<span class="elsevierStyleItalic">p</span> = 0.024) were lower in patients who survived compared with the levels in patients who died (<a class="elsevierStyleCrossRef" href="#tbl3">Table III</a>). Additionally, the eotaxin level increased significantly from day 1 to day 3 (day 3 – day 1) in the patients who died (<span class="elsevierStyleItalic">p</span> = 0.023), as shown in <a class="elsevierStyleCrossRef" href="#tbl3">Table III</a>. <a class="elsevierStyleCrossRef" href="#fig2">Figure 2</a> shows the ROC curve used to define the best cut-off levels for these markers using death as an endpoint. Due to technical reasons, only 24 of the 37 (65%) episodes had the plasma PCT level tested at inclusion. Therefore, a ROC curve was independently constructed for this marker (data not shown). Based on this curve, a PCT level greater than 1.2 μg/L was associated with 28-day mortality, with a sensitivity of 77% and a specificity of 54%.</p><elsevierMultimedia ident="tbl3"></elsevierMultimedia><elsevierMultimedia ident="fig2"></elsevierMultimedia></span></span><span id="cesec130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle180">DISCUSSION</span><p id="para230" class="elsevierStylePara elsevierViewall">Clinical information is often limited when predicting the outcome of neutropenic onco-hematological patients. In this study, 9 (29%) of 31 patients died during the follow-up period, even though their MASCC score was high. Conversely, only one death occurred in the patients classified as high risk based on the MASCC index (data not shown). Inflammatory markers may be a potential tool to enhance the accuracy of risk stratification in neutropenic onco-hematological patients. Several endpoints and multiple inflammatory molecules have been tested in the literature; however, the available data are contradictory, and a reliable biomarker has yet to be found.<a class="elsevierStyleCrossRef" href="#bib12">12-13</a>,</p><p id="para240" class="elsevierStylePara elsevierViewall">In this pilot study, we were unable to demonstrate any association between the studied inflammatory molecules and bacteremia. This finding contrasts with the results of previous studies.<a class="elsevierStyleCrossRefs" href="#bib13">13–14</a> For instance, Kern and colleagues evaluated the association between circulating levels of IL-8 and bacteremia resulting from Gram-negative bacilli in 133 patients with febrile neutropenia. They found that IL-8 levels above 2,000 pg/mL on the day of fever predicted bacteremia, with positive and negative predictive values of 73% and 94%, respectively.<a class="elsevierStyleCrossRef" href="#bib14">14</a> Lehrnbecher and colleagues found similar results studying IL-8 and both fungal infections and bacteremia induced by Gram-negative bacilli.<a class="elsevierStyleCrossRef" href="#bib21">21</a> In a smaller sample of neutropenic patients, von Lilienfeld-Toal et al. demonstrated that, in contrast with the C-reactive protein level, both the PCT and IL-6 levels were significantly higher in bacteremic patients than in patients presenting with pneumonia but not bacteremia, fever of unknown origin or non-infectious fever.<a class="elsevierStyleCrossRef" href="#bib22">22</a></p><p id="para250" class="elsevierStylePara elsevierViewall">The requirement for a change in antibiotic regimen was used as a surrogate indicator for an inadequate response to the antimicrobial therapy. The day 3 circulating levels of PCT, sTNF-R II, IL-8, and MCP-1 were significantly higher in patients requiring antibiotic regimen modification compared with the levels in patients who were maintained on their initial regimen. Most importantly, the PCT level on the day of fever presentation (i.e., at inclusion) and the sTNF-R II level on day 1 were also associated with all-cause 28-day mortality, as they were significantly higher in the patients who died. TNF receptors are expressed on the cell membrane of virtually all nucleated cells. Following a bacterial insult, soluble TNF receptors can be detected earlier than TNF-α; however, their half-life is only 6 to 20 minutes.<a class="elsevierStyleCrossRef" href="#bib23">23</a> While TNF-R I can mediate almost all TNF-α-associated activities, at physiological levels, TNF-R II only shows signal transduction activity in a few cell types, such as T cells. The inducible expression of TNF-R II might fulfill other important functions, such as the functional neutralization and clearance of TNF from the circulation.<a class="elsevierStyleCrossRef" href="#bib24">24</a> To the best of our knowledge, soluble type I and type II TNF receptors have never been tested as markers for clinical risk assessment in adult onco-hematological patients.</p><p id="para260" class="elsevierStylePara elsevierViewall">PCT is a precursor of calcitonin and is expressed by most parenchymal organs during a systemic inflammatory response, especially responses associated with bacterial infections.<a class="elsevierStyleCrossRef" href="#bib25">25</a> PCT has been investigated in several clinical settings and has been shown to be a useful diagnostic and prognostic marker<a class="elsevierStyleCrossRef" href="#bib26">26</a> as well as a potential therapeutic guide.<a class="elsevierStyleCrossRef" href="#bib27">27</a> Along with IL-8 and IL-6, PCT is one of the most studied biomarkers in neutropenic patients. Even though some negative results have been published,<a class="elsevierStyleCrossRef" href="#bib20">20</a> most studies suggest that PCT has diagnostic potential in neutropenic patients. In this context, Persson and colleagues demonstrated that the PCT level rose within two days of the onset of febrile neutropenia and was sustained in patients who were more likely to develop severe or unstable infections compared with patients who presented with no complications.<a class="elsevierStyleCrossRef" href="#bib28">28</a> In another study, the same group demonstrated that the PCT level was more accurate than the C-reactive protein level in discriminating febrile neutropenic patients with bacteremia from those without bacteremia;<a class="elsevierStyleCrossRef" href="#bib13">13</a> similar results have been published by Massaro et al.<a class="elsevierStyleCrossRef" href="#bib29">29</a> Finally, in an observational, multicenter European study with 158 neutropenic patients, Giamarellou and colleagues showed that a PCT level above 5 ng/mL strongly suggests the presence of severe sepsis.<a class="elsevierStyleCrossRef" href="#bib30">30</a></p><p id="para270" class="elsevierStylePara elsevierViewall">In addition to sTNF-R II, MCP-1, and PCT, the change in eotaxin levels from day 1 to day 3 was significantly associated with all-cause 28-day mortality. The eotaxin level significantly increased from inclusion to the third day of follow-up in patients who did not survive. This association between eotaxin level and 28-day mortality in neutropenic patients was a surprising finding. Eotaxin acts primarily as a chemokine, recruiting eosinophils via CCR3. Eotaxin has been shown to play a role in human allergic diseases<a class="elsevierStyleCrossRef" href="#bib31">31</a> and can attract cell types other than eosinophils under certain circumstances.<a class="elsevierStyleCrossRef" href="#bib32">32</a> However, neither the sTNF receptors nor eotaxin has been evaluated as a risk factor in febrile neutropenia.</p><p id="para280" class="elsevierStylePara elsevierViewall">It should be noted that there are limitations to this study. First, this was a single-center study with a small number of patients, which limits the generalizability of the results. For instance, the small sample size, along with the low frequency of bacteremia (35%) observed among the studied patients, might have prevented us from detecting any association between bacteremia and the investigated markers. However, this was a pilot study, and these results will be verified in a larger cohort with a pre-defined sample of patients. Second, some patients with more than one neutropenic episode were included, potentially leading to an underestimation of the number of deaths. Third, only 35% of the studied episodes presented with bacteremia; most cases of fever were not microbiologically confirmed as infectious fever. Due to the small number of patients, we were unable to evaluate patient subgroups (e.g., confirmed and unconfirmed infections) for the other studied endpoints. Finally, some patients had undergone blood marrow transplantation, which increases the heterogeneity of the studied population. As this was an initial, pilot study, some of these limitations were anticipated. Our group is currently conducting complementary studies with a larger number of patients, focusing on the most promising markers.</p><p id="para290" class="elsevierStylePara elsevierViewall">In conclusion, in this pilot study, we examined the predictive potential of different biological markers in 37 episodes of febrile neutropenia occurring in 31 patients with an onco-hematological diagnosis. The PCT, sTNF-R II, IL-8, eotaxin, and MCP-1 levels, measured at different times during the first three days of follow-up were significantly associated with all-cause 28-day mortality and/or the requirement for a change in antibiotic therapy. None of the studied molecules were able to differentiate febrile neutropenic patients with bacteremia from those patients without bacteremia. Because this was a pilot study, our findings must be confirmed in a larger prospective, multicenter cohort.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:7 [ 0 => array:2 [ "identificador" => "xpalclavsec1582217" "titulo" => "KEYWORDS" ] 1 => array:2 [ "identificador" => "cesec10" "titulo" => "INTRODUCTION" ] 2 => array:3 [ "identificador" => "cesec20" "titulo" => "MATERIAL AND METHODS" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "cesec30" "titulo" => "Patients and settings" ] 1 => array:2 [ "identificador" => "cesec40" "titulo" => "Endpoints" ] 2 => array:2 [ "identificador" => "cesec50" "titulo" => "Procedures" ] 3 => array:2 [ "identificador" => "cesec60" "titulo" => "Laboratory exams" ] 4 => array:2 [ "identificador" => "cesec70" "titulo" => "Statistical analysis" ] ] ] 3 => array:3 [ "identificador" => "cesec80" "titulo" => "RESULTS" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "cesec90" "titulo" => "Characteristics of the patients" ] 1 => array:2 [ "identificador" => "cesec100" "titulo" => "Inflammatory molecules and antibiotic regimen change" ] 2 => array:2 [ "identificador" => "cesec110" "titulo" => "Inflammatory molecules and bacteremia" ] 3 => array:2 [ "identificador" => "cesec120" "titulo" => "Inflammatory molecules and all-cause 28-day mortality" ] ] ] 4 => array:2 [ "identificador" => "cesec130" "titulo" => "DISCUSSION" ] 5 => array:2 [ "identificador" => "xack639231" "titulo" => "ACKNOWLEDGEMENTS" ] 6 => array:1 [ "titulo" => "REFERENCES" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2011-04-23" "fechaAceptado" => "2011-06-19" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "KEYWORDS" "identificador" => "xpalclavsec1582217" "palabras" => array:5 [ 0 => "Febrile neutropenia" 1 => "Inflammatory markers" 2 => "Procalcitonin" 3 => "Sensitivity" 4 => "Specificity" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "resumen" => "<span id="ceabs10" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle10">OBJECTIVE:</span><p id="spara60" class="elsevierStyleSimplePara elsevierViewall">This study aimed to examine the association between different inflammatory markers and specific clinical endpoints in patients with febrile neutropenia.</p></span> <span id="ceabs20" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle20">METHOD:</span><p id="spara70" class="elsevierStyleSimplePara elsevierViewall">We prospectively evaluated the expression of procalcitonin (PCT), interleukin 8 (IL-8), induced protein-10, tumor necrosis factor alpha (TNF-α), two soluble TNF-α receptors (sTNF-R I and sTNF-R II), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha, and eotaxin in 37 episodes of febrile neutropenia occurring in 31 hospitalized adult onco-hematologic patients. Peripheral blood samples were collected in the morning at inclusion (day of fever onset) and on days 1, 3, and 7 after the onset of fever. Approximately 2–3 ml of plasma was obtained from each blood sample and stored at -80°C.</p></span> <span id="ceabs30" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle30">RESULTS:</span><p id="spara80" class="elsevierStyleSimplePara elsevierViewall">The sTNF-R II level at inclusion (day 1), the PCT level on the day of fever onset, and the change (day 3 - day 1) in the IL-8 and eotaxin levels were significantly higher in patients who died during the 28-day follow-up. A requirement for early adjustment of antimicrobial treatment was associated with higher day 3 levels of IL-8, sTNF-R II, PCT, and MCP-1.</p></span> <span id="ceabs40" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cestitle40">CONCLUSION:</span><p id="spara90" class="elsevierStyleSimplePara elsevierViewall">Procalcitonin, sTNF-R II, IL-8, MCP-1, and eotaxin could potentially be used to assess the risk of death and the requirement for early adjustment of antimicrobial treatment in febrile, neutropenic onco-hematologic patients. The levels of the other markers showed no association with any of the evaluated endpoints.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "ceabs10" "titulo" => "OBJECTIVE:" ] 1 => array:2 [ "identificador" => "ceabs20" "titulo" => "METHOD:" ] 2 => array:2 [ "identificador" => "ceabs30" "titulo" => "RESULTS:" ] 3 => array:2 [ "identificador" => "ceabs40" "titulo" => "CONCLUSION:" ] ] ] ] "NotaPie" => array:1 [ 0 => array:1 [ "nota" => "<p class="elsevierStyleNotepara" id="cenpara10">No potential conflict of interest was reported.</p>" ] ] "multimedia" => array:5 [ 0 => array:7 [ "identificador" => "fig1" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 434 "Ancho" => 442 "Tamanyo" => 21801 ] ] "descripcion" => array:1 [ "en" => "<p id="spara10" class="elsevierStyleSimplePara elsevierViewall">ROC curve showing the accuracy of the four inflammatory molecules significantly associated with a change in antibiotic therapy within the first 72 h of therapy. The corresponding AUC values were 0.683 (CI 95%: 0.477–0.899) for PCT, 0.758 (CI 95%: 0.572–0.944) for MCP-1, 0.683 (95% CI: 0.470–0.896) for IL-8, and 0.696 (95% CI: 469–922) for sTNF-R II; all data were collected at day 3 following inclusion.</p>" ] ] 1 => array:7 [ "identificador" => "fig2" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 445 "Ancho" => 452 "Tamanyo" => 19225 ] ] "descripcion" => array:1 [ "en" => "<p id="spara20" class="elsevierStyleSimplePara elsevierViewall">ROC curve showing the accuracy of the three inflammatory molecules significantly associated with 28-day all-cause mortality. The AUC values were 0.728 (95% CI: 0.508–0.948) for ΔIL-8 (day3 - day1), 0.767 (CI 95%: 0.575–0.958) for Δeotaxin (day3 – day 1), and 0.750 (95% CI: 565–935) for sTNF-R II measured at day 1.</p>" ] ] 2 => array:7 [ "identificador" => "tbl1" "etiqueta" => "Table I" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Characteristic \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top">Gender, <span class="elsevierStyleItalic">n (%)</span>    <span class="elsevierStyleItalic">Female</span><span class="elsevierStyleItalic">Male</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">8 (25.8)23 (74.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top">Age, <span class="elsevierStyleItalic">mean (SD)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">38.5 (12.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="top">Hematological diagnosis, <span class="elsevierStyleItalic">n (%)</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Acute myeloid leukemia</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">10 (32.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Non-Hodgkin's lymphoma</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">7 (22.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Multiple myeloma</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">5 (16.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Acute lymphoid leukemia</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">2 (6.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Myelodysplastic syndrome</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">2 (6.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Aplastic anemia</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">2 (6.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Hodgkin's lymphoma</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">2 (6.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Chronic myeloid leukemia</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">1 (3.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="top">Disease burden, <span class="elsevierStyleItalic">n (%)</span><a class="elsevierStyleCrossRef" href="#tfn1">∫</a></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Remission</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">16 (43) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Activity</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">21 (57) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top">Charlson's score, <span class="elsevierStyleItalic">n (%)</span><a class="elsevierStyleCrossRef" href="#tfn1">∫</a><a class="elsevierStyleCrossRef" href="#tfn2">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span>0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">27 (82) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span>1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">3 (9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top"><span class="elsevierStyleHsp" style=""></span>2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">2 (6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top" style="border-bottom: 2px solid black"><span class="elsevierStyleHsp" style=""></span>4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">1 (3) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tfn1" "etiqueta" => "∫" "nota" => "<p class="elsevierStyleNotepara" id="cenpara20">The total here corresponds to the number of episodes (<span class="elsevierStyleItalic">n</span> = 37).</p>" ] 1 => array:3 [ "identificador" => "tfn2" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="cenpara30">Charlson's scores were not available for four episodes.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara30" class="elsevierStyleSimplePara elsevierViewall">Main characteristics of the studied patients.</p>" ] ] 3 => array:7 [ "identificador" => "tbl2" "etiqueta" => "Table II" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="top" scope="col">Inflammatory marker \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">Cut-off \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">Sensitivity \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">Specificity \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">PPV<a class="elsevierStyleCrossRef" href="#tfn3">'</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">NPV<a class="elsevierStyleCrossRef" href="#tfn4">∫</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">+LR<a class="elsevierStyleCrossRef" href="#tfn5">§</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">-LR<a class="elsevierStyleCrossRef" href="#tfn6"><span class="elsevierStyleSup">¶</span></a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col"><span class="elsevierStyleItalic">p</span>-value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">IL-8<a class="elsevierStyleCrossRef" href="#tfn7">∞</a> day 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">218 pg/mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">72% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">80% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">61% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">86% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">3.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.047 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">sTNF-R II<a class="elsevierStyleCrossRef" href="#tfn13a">¥</a> day 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">4000 pg/mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">72% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">88% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">61% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">87% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">6.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.036 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top">MCP-1<a class="elsevierStyleCrossRef" href="#tfn8">Δ</a> day 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">1520 pg/mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">72% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">84% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">66% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">86% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">4.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.008 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="top" style="border-bottom: 2px solid black">PCT day 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">4.8 μg/L \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">45% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">96% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">83% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">80% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">11.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">0.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">0.038 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:7 [ 0 => array:3 [ "identificador" => "tfn3" "etiqueta" => "'" "nota" => "<p class="elsevierStyleNotepara" id="cenpara40">Positive predictive value;</p>" ] 1 => array:3 [ "identificador" => "tfn4" "etiqueta" => "∫" "nota" => "<p class="elsevierStyleNotepara" id="cenpara50">Negative predictive value;</p>" ] 2 => array:3 [ "identificador" => "tfn5" "etiqueta" => "§" "nota" => "<p class="elsevierStyleNotepara" id="cenpara60">Positive likelihood ratio;</p>" ] 3 => array:3 [ "identificador" => "tfn6" "etiqueta" => "¶" "nota" => "<p class="elsevierStyleNotepara" id="cenpara70">Negative likelihood ratio;</p>" ] 4 => array:3 [ "identificador" => "tfn13a" "etiqueta" => "¥" "nota" => "<p class="elsevierStyleNotepara" id="cenpara80">Soluble TNF receptor type II;</p>" ] 5 => array:3 [ "identificador" => "tfn7" "etiqueta" => "∞" "nota" => "<p class="elsevierStyleNotepara" id="cenpara90">Interleukine 8;</p>" ] 6 => array:3 [ "identificador" => "tfn8" "etiqueta" => "Δ" "nota" => "<p class="elsevierStyleNotepara" id="cenpara100">Monocyte chemotactic protein-1.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara40" class="elsevierStyleSimplePara elsevierViewall">Best cut-off values and accuracy of the inflammatory markers associated with a change in antibiotic therapy within the first 72 h of therapy. The cut-offs were defined using the ROC curve.</p>" ] ] 4 => array:7 [ "identificador" => "tbl3" "etiqueta" => "Table III" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="cenpara160" class="elsevierStyleSimplePara elsevierViewall">∞ Interleukin 8.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="justify" valign="top" scope="col">Inflammatory marker \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">Cut-off \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">Sensitivity \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">Specificity \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">PPV<a class="elsevierStyleCrossRef" href="#tfn9">'</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">NPV<a class="elsevierStyleCrossRef" href="#tfn10">∫</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">+LR<a class="elsevierStyleCrossRef" href="#tfn11">§</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col">-LR<a class="elsevierStyleCrossRef" href="#tfn12">¶</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="top" scope="col"><span class="elsevierStyleItalic">p-</span>value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top">sTNF-R II<a class="elsevierStyleCrossRef" href="#tfn13">¥</a> day 1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">3740 pg/μL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">89% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">60% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">50% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">92% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top">0.034 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="justify" valign="top" style="border-bottom: 2px solid black">Δeotaxin (day 3-day 1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">28 pg/μL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">55% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">85% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">63% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">81% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">3.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">0.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="top" style="border-bottom: 2px solid black">0.023 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:5 [ 0 => array:3 [ "identificador" => "tfn9" "etiqueta" => "'" "nota" => "<p class="elsevierStyleNotepara" id="cenpara110">Positive predictive value;</p>" ] 1 => array:3 [ "identificador" => "tfn10" "etiqueta" => "∫" "nota" => "<p class="elsevierStyleNotepara" id="cenpara120">Negative predictive value;</p>" ] 2 => array:3 [ "identificador" => "tfn11" "etiqueta" => "§" "nota" => "<p class="elsevierStyleNotepara" id="cenpara130">Positive likelihood ratio;</p>" ] 3 => array:3 [ "identificador" => "tfn12" "etiqueta" => "¶" "nota" => "<p class="elsevierStyleNotepara" id="cenpara140">Negative likelihood ratio;</p>" ] 4 => array:3 [ "identificador" => "tfn13" "etiqueta" => "¥" "nota" => "<p class="elsevierStyleNotepara" id="cenpara150">Soluble TNF receptor type II;</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spara50" class="elsevierStyleSimplePara elsevierViewall">Best cut-off values and accuracy of the inflammatory markers associated with 28-day all-cause mortality. The cut-offs were defined using the ROC curve.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "REFERENCES" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec10" "bibliografiaReferencia" => array:32 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ GP Bodey \n \t\t\t\t\t\t\t\t """ 1 => """ M Buckley \n \t\t\t\t\t\t\t\t """ 2 => """ YS Sathe \n \t\t\t\t\t\t\t\t """ 3 => """ EJ Freireich \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-64-2-328" "Revista" => array:7 [ "tituloSerie" => "Ann Intern Med" "fecha" => "1966" "volumen" => "64" "paginaInicial" => "328" "paginaFinal" => "340" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/5216294" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028217319441" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ S Schimpff \n \t\t\t\t\t\t\t\t """ 1 => """ W Satterlee \n \t\t\t\t\t\t\t\t """ 2 => """ VM Young \n \t\t\t\t\t\t\t\t """ 3 => """ A Serpick \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1056/NEJM197105132841904" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1971" "volumen" => "284" "paginaInicial" => "1061" "paginaFinal" => "1065" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4994878" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1056/NEJM197105132841904" "WWW" => array:1 [ "link" => "10.1056/NEJM197105132841904" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ WT Hughes \n \t\t\t\t\t\t\t\t """ 1 => """ D Armstrong \n \t\t\t\t\t\t\t\t """ 2 => """ GP Bodey \n \t\t\t\t\t\t\t\t """ 3 => """ EJ Bow \n \t\t\t\t\t\t\t\t """ 4 => """ AE Brown \n \t\t\t\t\t\t\t\t """ 5 => """ T Calandra \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1086/339215" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2002" "volumen" => "34" "paginaInicial" => "730" "paginaFinal" => "751" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11850858" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028221021294" "estado" => "S300" "issn" => "00150282" ] ] ] 1 => array:2 [ "doi" => "10.1086/339215" "WWW" => array:1 [ "link" => "10.1086/339215" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ C Viscoli \n \t\t\t\t\t\t\t\t """ 1 => """ P Bruzzi \n \t\t\t\t\t\t\t\t """ 2 => """ E Castagnola \n \t\t\t\t\t\t\t\t """ 3 => """ L Boni \n \t\t\t\t\t\t\t\t """ 4 => """ T Calandra \n \t\t\t\t\t\t\t\t """ 5 => """ H Gaya \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/0959-8049(94)90412-x" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer" "fecha" => "1994" "volumen" => "30A" "paginaInicial" => "430" "paginaFinal" => "437" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8018397" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/0959-8049(94)90412-x" "WWW" => array:1 [ "link" => "10.1016/0959-8049(94)90412-X" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Is it time to redefine the management of febrile neutropenia in cancer patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ EJ Anaissie \n \t\t\t\t\t\t\t\t """ 1 => """ S Vadhan-Raj \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/S0002-9343(99)80366-0" "Revista" => array:6 [ "tituloSerie" => "Am J Med" "fecha" => "1995" "volumen" => "98" "paginaInicial" => "221" "paginaFinal" => "223" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7872336" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/S0002-9343(99)80366-0" "WWW" => array:1 [ "link" => "10.1016/S0002-9343(99)80366-0" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Freifeld \n \t\t\t\t\t\t\t\t """ 1 => """ D Marchigiani \n \t\t\t\t\t\t\t\t """ 2 => """ T Walsh \n \t\t\t\t\t\t\t\t """ 3 => """ S Chanock \n \t\t\t\t\t\t\t\t """ 4 => """ L Lewis \n \t\t\t\t\t\t\t\t """ 5 => """ J Hiemenz \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1056/NEJM199907293410501" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1999" "volumen" => "341" "paginaInicial" => "305" "paginaFinal" => "311" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10423464" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1056/NEJM199907293410501" "WWW" => array:1 [ "link" => "10.1056/NEJM199907293410501" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ WV Kern \n \t\t\t\t\t\t\t\t """ 1 => """ A Cometta \n \t\t\t\t\t\t\t\t """ 2 => """ R De Bock \n \t\t\t\t\t\t\t\t """ 3 => """ J Langenaeken \n \t\t\t\t\t\t\t\t """ 4 => """ M Paesmans \n \t\t\t\t\t\t\t\t """ 5 => """ H Gaya \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1056/NEJM199907293410502" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "1999" "volumen" => "341" "paginaInicial" => "312" "paginaFinal" => "318" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10423465" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028215002484" "estado" => "S300" "issn" => "00150282" ] ] ] 1 => array:2 [ "doi" => "10.1056/NEJM199907293410502" "WWW" => array:1 [ "link" => "10.1056/NEJM199907293410502" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ JA Talcott \n \t\t\t\t\t\t\t\t """ 1 => """ R Finberg \n \t\t\t\t\t\t\t\t """ 2 => """ RJ Mayer \n \t\t\t\t\t\t\t\t """ 3 => """ L Goldman \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "1988" "volumen" => "148" "paginaInicial" => "2561" "paginaFinal" => "2568" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3196123" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ JA Talcott \n \t\t\t\t\t\t\t\t """ 1 => """ RD Siegel \n \t\t\t\t\t\t\t\t """ 2 => """ R Finberg \n \t\t\t\t\t\t\t\t """ 3 => """ L Goldman \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.1992.10.2.316" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1992" "volumen" => "10" "paginaInicial" => "316" "paginaFinal" => "322" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1732432" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028217304211" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ J Klastersky \n \t\t\t\t\t\t\t\t """ 1 => """ M Paesmans \n \t\t\t\t\t\t\t\t """ 2 => """ EB Rubenstein \n \t\t\t\t\t\t\t\t """ 3 => """ M Boyer \n \t\t\t\t\t\t\t\t """ 4 => """ L Elting \n \t\t\t\t\t\t\t\t """ 5 => """ R Feld \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2000.18.16.3038" "Revista" => array:7 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2000" "volumen" => "18" "paginaInicial" => "3038" "paginaFinal" => "3051" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10944139" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028212023916" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ M Paesmans \n \t\t\t\t\t\t\t\t """ 1 => """ JP Sculier \n \t\t\t\t\t\t\t\t """ 2 => """ J Lecomte \n \t\t\t\t\t\t\t\t """ 3 => """ J Thiriaux \n \t\t\t\t\t\t\t\t """ 4 => """ P Libert \n \t\t\t\t\t\t\t\t """ 5 => """ R Sergysels \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2000" "volumen" => "89" "paginaInicial" => "523" "paginaFinal" => "533" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10931451" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6" "WWW" => array:1 [ "link" => "10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ N Buyukberber \n \t\t\t\t\t\t\t\t """ 1 => """ S Buyukberber \n \t\t\t\t\t\t\t\t """ 2 => """ A Sevinc \n \t\t\t\t\t\t\t\t """ 3 => """ C Camci \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1007/s12032-008-9081-z" "Revista" => array:6 [ "tituloSerie" => "Med Oncol" "fecha" => "2009" "volumen" => "26" "paginaInicial" => "55" "paginaFinal" => "61" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18686048" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1007/s12032-008-9081-z" "WWW" => array:1 [ "link" => "10.1007/s12032-008-9081-z" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ L Persson \n \t\t\t\t\t\t\t\t """ 1 => """ P Engervall \n \t\t\t\t\t\t\t\t """ 2 => """ A Magnuson \n \t\t\t\t\t\t\t\t """ 3 => """ T Vikerfors \n \t\t\t\t\t\t\t\t """ 4 => """ B Soderquist \n \t\t\t\t\t\t\t\t """ 5 => """ LO Hansson \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1080/00365540410020217" "Revista" => array:6 [ "tituloSerie" => "Scand J Infect Dis" "fecha" => "2004" "volumen" => "36" "paginaInicial" => "365" "paginaFinal" => "371" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15287382" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1080/00365540410020217" "WWW" => array:1 [ "link" => "10.1080/00365540410020217" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ WV Kern \n \t\t\t\t\t\t\t\t """ 1 => """ M Heiss \n \t\t\t\t\t\t\t\t """ 2 => """ G Steinbach \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1086/319207" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2001" "volumen" => "32" "paginaInicial" => "832" "paginaFinal" => "835" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11229856" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1086/319207" "WWW" => array:1 [ "link" => "10.1086/319207" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ ES de Bont \n \t\t\t\t\t\t\t\t """ 1 => """ E Vellenga \n \t\t\t\t\t\t\t\t """ 2 => """ JC Swaanenburg \n \t\t\t\t\t\t\t\t """ 3 => """ V Fidler \n \t\t\t\t\t\t\t\t """ 4 => """ PJ Visser-van Brummen \n \t\t\t\t\t\t\t\t """ 5 => """ WA Kamps \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1046/j.1365-2141.1999.01707.x" "Revista" => array:7 [ "tituloSerie" => "Br J Haematol" "fecha" => "1999" "volumen" => "107" "paginaInicial" => "375" "paginaFinal" => "380" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10583227" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028220326236" "estado" => "S300" "issn" => "00150282" ] ] ] 1 => array:2 [ "doi" => "10.1046/j.1365-2141.1999.01707.x" "WWW" => array:1 [ "link" => "10.1046/j.1365-2141.1999.01707.x" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Febrile neutropenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => """ M Ellis \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1196/annals.1414.035" "Revista" => array:6 [ "tituloSerie" => "Ann N Y Acad Sci" "fecha" => "2008" "volumen" => "1138" "paginaInicial" => "329" "paginaFinal" => "350" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18837909" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1196/annals.1414.035" "WWW" => array:1 [ "link" => "10.1196/annals.1414.035" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ ME Charlson \n \t\t\t\t\t\t\t\t """ 1 => """ P Pompei \n \t\t\t\t\t\t\t\t """ 2 => """ KL Ales \n \t\t\t\t\t\t\t\t """ 3 => """ CR MacKenzie \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/0021-9681(87)90171-8" "Revista" => array:6 [ "tituloSerie" => "J Chronic Dis" "fecha" => "1987" "volumen" => "40" "paginaInicial" => "373" "paginaFinal" => "383" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3558716" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/0021-9681(87)90171-8" "WWW" => array:1 [ "link" => "10.1016/0021-9681(87)90171-8" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Toxicity and response criteria of the Eastern Cooperative Oncology Group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ MM Oken \n \t\t\t\t\t\t\t\t """ 1 => """ RH Creech \n \t\t\t\t\t\t\t\t """ 2 => """ DC Tormey \n \t\t\t\t\t\t\t\t """ 3 => """ J Horton \n \t\t\t\t\t\t\t\t """ 4 => """ TE Davis \n \t\t\t\t\t\t\t\t """ 5 => """ ET McFadden \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Oncol" "fecha" => "1982" "volumen" => "5" "paginaInicial" => "649" "paginaFinal" => "655" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7165009" "web" => "Medline" ] ] ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "10.1097/00000421-198212000-00014" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ PM Bossuyt \n \t\t\t\t\t\t\t\t """ 1 => """ JB Reitsma \n \t\t\t\t\t\t\t\t """ 2 => """ DE Bruns \n \t\t\t\t\t\t\t\t """ 3 => """ CA Gatsonis \n \t\t\t\t\t\t\t\t """ 4 => """ PP Glasziou \n \t\t\t\t\t\t\t\t """ 5 => """ LM Irwig \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/0003-4819-138-1-200301070-00010" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2003" "volumen" => "138" "paginaInicial" => "40" "paginaFinal" => "44" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12513043" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ ES de Bont \n \t\t\t\t\t\t\t\t """ 1 => """ E Vellenga \n \t\t\t\t\t\t\t\t """ 2 => """ J Swaanenburg \n \t\t\t\t\t\t\t\t """ 3 => """ W Kamps \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1007/s150100070014" "Revista" => array:6 [ "tituloSerie" => "Infection" "fecha" => "2000" "volumen" => "28" "paginaInicial" => "398" "paginaFinal" => "400" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11139163" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1007/s150100070014" "WWW" => array:1 [ "link" => "10.1007/s150100070014" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of fungal infections in neutropenic children" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ T Lehrnbecher \n \t\t\t\t\t\t\t\t """ 1 => """ AH Groll \n \t\t\t\t\t\t\t\t """ 2 => """ SJ Chanock \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1097/00008480-199902000-00010" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pediatr" "fecha" => "1999" "volumen" => "11" "paginaInicial" => "47" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10084084" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1097/00008480-199902000-00010" "WWW" => array:1 [ "link" => "10.1097/00008480-199902000-00010" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ M von Lilienfeld-Toal \n \t\t\t\t\t\t\t\t """ 1 => """ MP Dietrich \n \t\t\t\t\t\t\t\t """ 2 => """ A Glasmacher \n \t\t\t\t\t\t\t\t """ 3 => """ L Lehmann \n \t\t\t\t\t\t\t\t """ 4 => """ P Breig \n \t\t\t\t\t\t\t\t """ 5 => """ C Hahn \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10096-004-1156-y" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Microbiol Infect Dis" "fecha" => "2004" "volumen" => "23" "paginaInicial" => "539" "paginaFinal" => "544" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15221617" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor: a pleiotropic cytokine and therapeutic target" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => """ KJ Tracey \n \t\t\t\t\t\t\t\t """ 1 => """ A Cerami \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1146/annurev.med.45.1.491" "Revista" => array:6 [ "tituloSerie" => "Annu Rev Med" "fecha" => "1994" "volumen" => "45" "paginaInicial" => "491" "paginaFinal" => "503" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8198398" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1146/annurev.med.45.1.491" "WWW" => array:1 [ "link" => "10.1146/annurev.med.45.1.491" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Two tumour necrosis factor receptors: structure and function" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ P Vandenabeele \n \t\t\t\t\t\t\t\t """ 1 => """ W Declercq \n \t\t\t\t\t\t\t\t """ 2 => """ R Beyaert \n \t\t\t\t\t\t\t\t """ 3 => """ W Fiers \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1016/s0962-8924(00)89088-1" "Revista" => array:6 [ "tituloSerie" => "Trends Cell Biol" "fecha" => "1995" "volumen" => "5" "paginaInicial" => "392" "paginaFinal" => "399" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14732063" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1016/s0962-8924(00)89088-1" "WWW" => array:1 [ "link" => "10.1016/S0962-8924(00)89088-1" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => """ KL Becker \n \t\t\t\t\t\t\t\t """ 1 => """ R Snider \n \t\t\t\t\t\t\t\t """ 2 => """ ES Nylen \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1097/CCM.0B013E318165BABB" "Revista" => array:6 [ "tituloSerie" => "Crit Care Med" "fecha" => "2008" "volumen" => "36" "paginaInicial" => "941" "paginaFinal" => "952" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18431284" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1097/CCM.0B013E318165BABB" "WWW" => array:1 [ "link" => "10.1097/CCM.0B013E318165BABB" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ S Harbarth \n \t\t\t\t\t\t\t\t """ 1 => """ K Holeckova \n \t\t\t\t\t\t\t\t """ 2 => """ C Froidevaux \n \t\t\t\t\t\t\t\t """ 3 => """ D Pittet \n \t\t\t\t\t\t\t\t """ 4 => """ B Ricou \n \t\t\t\t\t\t\t\t """ 5 => """ GE Grau \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/ajrccm.164.3.2009052" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2001" "volumen" => "164" "paginaInicial" => "396" "paginaFinal" => "402" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11500339" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ M Christ-Crain \n \t\t\t\t\t\t\t\t """ 1 => """ D Stolz \n \t\t\t\t\t\t\t\t """ 2 => """ R Bingisser \n \t\t\t\t\t\t\t\t """ 3 => """ C Muller \n \t\t\t\t\t\t\t\t """ 4 => """ D Miedinger \n \t\t\t\t\t\t\t\t """ 5 => """ PR Huber \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1164/rccm.200512-1922OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2006" "volumen" => "174" "paginaInicial" => "84" "paginaFinal" => "93" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16603606" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1164/rccm.200512-1922OC" "WWW" => array:1 [ "link" => "10.1164/rccm.200512-1922OC" ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => """ L Persson \n \t\t\t\t\t\t\t\t """ 1 => """ B Soderquist \n \t\t\t\t\t\t\t\t """ 2 => """ P Engervall \n \t\t\t\t\t\t\t\t """ 3 => """ T Vikerfors \n \t\t\t\t\t\t\t\t """ 4 => """ LO Hansson \n \t\t\t\t\t\t\t\t """ 5 => """ U Tidefelt \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1111/j.1600-0609.2004.00387.x" "Revista" => array:7 [ "tituloSerie" => "Eur J Haematol" "fecha" => "2005" "volumen" => "74" "paginaInicial" => "297" "paginaFinal" => "303" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15777341" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028220307111" "estado" => "S300" "issn" => "00150282" ] ] ] 1 => array:2 [ "doi" => "10.1111/j.1600-0609.2004.00387.x" "WWW" => array:1 [ "link" => "10.1111/j.1600-0609.2004.00387.x" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ KS Massaro \n \t\t\t\t\t\t\t\t """ 1 => """ SF Costa \n \t\t\t\t\t\t\t\t """ 2 => """ C Leone \n \t\t\t\t\t\t\t\t """ 3 => """ DA Chamone \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1186/1471-2334-7-137" "Revista" => array:6 [ "tituloSerie" => "BMC Infect Dis" "fecha" => "2007" "volumen" => "7" "paginaInicial" => "137" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18034890" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028205034175" "estado" => "S300" "issn" => "00150282" ] ] ] 1 => array:2 [ "doi" => "10.1186/1471-2334-7-137" "WWW" => array:1 [ "link" => "10.1186/1471-2334-7-137" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ H Giamarellou \n \t\t\t\t\t\t\t\t """ 1 => """ EJ Giamarellos-Bourboulis \n \t\t\t\t\t\t\t\t """ 2 => """ P Repoussis \n \t\t\t\t\t\t\t\t """ 3 => """ L Galani \n \t\t\t\t\t\t\t\t """ 4 => """ N Anagnostopoulos \n \t\t\t\t\t\t\t\t """ 5 => """ P Grecka \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1111/j.1469-0691.2004.00883.x" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2004" "volumen" => "10" "paginaInicial" => "628" "paginaFinal" => "633" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15214875" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028219324811" "estado" => "S300" "issn" => "00150282" ] ] ] 1 => array:2 [ "doi" => "10.1111/j.1469-0691.2004.00883.x" "WWW" => array:1 [ "link" => "10.1111/j.1469-0691.2004.00883.x" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemokines in asthma: cooperative interaction between chemokines and IL-13" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => """ N Zimmermann \n \t\t\t\t\t\t\t\t """ 1 => """ GK Hershey \n \t\t\t\t\t\t\t\t """ 2 => """ PS Foster \n \t\t\t\t\t\t\t\t """ 3 => """ ME Rothenberg \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.1067/mai.2003.139" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol" "fecha" => "2003" "volumen" => "111" "paginaInicial" => "227" "paginaFinal" => "42; quiz 43" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12589338" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.1067/mai.2003.139" "WWW" => array:1 [ "link" => "10.1067/mai.2003.139" ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => """ A Menzies-Gow \n \t\t\t\t\t\t\t\t """ 1 => """ S Ying \n \t\t\t\t\t\t\t\t """ 2 => """ I Sabroe \n \t\t\t\t\t\t\t\t """ 3 => """ VL Stubbs \n \t\t\t\t\t\t\t\t """ 4 => """ D Soler \n \t\t\t\t\t\t\t\t """ 5 => """ TJ Williams \n \t\t\t\t\t\t\t\t """ ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4049/jimmunol.169.5.2712" "Revista" => array:6 [ "tituloSerie" => "J Immunol" "fecha" => "2002" "volumen" => "169" "paginaInicial" => "2712" "paginaFinal" => "2718" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12193745" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack639231" "titulo" => "ACKNOWLEDGEMENTS" "texto" => "<p id="para300" class="elsevierStylePara elsevierViewall">The authors would like to thank the medical and nursing staff of the Hematology Division and Laboratorial Service at the Hospital das Clínicas da Universidade Federal de Minas Gerais for their participation in the study.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/18075932/0000006600000010/v1_202212011334/S1807593222023250/v1_202212011334/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/18075932/0000006600000010/v1_202212011334/S1807593222023250/v1_202212011334/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1807593222023250?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 8 | 3 | 11 |
2024 October | 40 | 34 | 74 |
2024 September | 37 | 14 | 51 |
2024 August | 40 | 19 | 59 |
2024 July | 39 | 21 | 60 |
2024 June | 30 | 8 | 38 |
2024 May | 29 | 13 | 42 |
2024 April | 30 | 14 | 44 |
2024 March | 62 | 10 | 72 |
2024 February | 42 | 10 | 52 |
2024 January | 33 | 13 | 46 |
2023 December | 28 | 13 | 41 |
2023 November | 31 | 22 | 53 |
2023 October | 32 | 21 | 53 |
2023 September | 32 | 22 | 54 |
2023 August | 14 | 10 | 24 |
2023 July | 10 | 11 | 21 |
2023 June | 23 | 11 | 34 |
2023 May | 41 | 3 | 44 |
2023 April | 44 | 1 | 45 |
2023 March | 63 | 3 | 66 |
2023 February | 24 | 2 | 26 |
2023 January | 18 | 1 | 19 |
2022 December | 30 | 5 | 35 |